Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.

Also called NCT01763918

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 331 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01763918
  • EudraCT 2012-001365-32
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, France, Germany, Hong Kong SAR China, Netherlands, New Zealand, Norway, South Africa, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01763918. Randomized; quadruple masking; primary purpose treatment. Start 2013-02-07 (actual); primary completion 2013-11-27 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Acronym
RUTHERFORD-2
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01763918
Content hash
2c5ee60e4fdffd4c03b4960e22ab67ec74d8c8cc3986064776323a4aed367e97